for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Puretech Health PLC

PRTC.L

現在値

247.00GBp

変化

1.00(+0.41%)

出来高

934,050

本日のレンジ

235.50

 - 

252.50

52週レンジ

145.80

 - 

375.50

∙ 約20分前の相場を表示しています。

適時開示

PureTech Health Says Company-Founded Entity Sonde Health Partners With Koye Pharma

Aug 24 (Reuters) - PureTech Health PLC <PRTC.L>::PURETECH HEALTH PLC - PRTC'S SONDE PARTNERS WITH KOYE PHARMACEUTICALS.PURETECH HEALTH - AGREEMENT TO DEVELOP A NEW VOCAL BIOMARKER DETECTION, MONITORING CAPABILITY FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN INDIA.PURETECH HEALTH - AS PART OF THIS ARRANGEMENT, KOYE WILL LEVERAGE SONDE'S VOCAL BIOMARKER DEVELOPMENT PLATFORM.PURETECH HEALTH - ARRANGEMENT WILL ALLOW KOYE TO DEVELOP SOLUTIONS THAT HELP TRACK AND TREAT RESPIRATORY HEALTH IN COPD PATIENTS USING THEIR VOICE.

PureTech Health Says FY Total Revenue Was $17.4 Mln

April 26 (Reuters) - PureTech Health PLC <PRTC.L>::PURETECH ANNOUNCES ANNUAL RESULTS FOR YEAR ENDED DECEMBER 31, 2021.PURETECH HEALTH: REVIEWING CAPITAL ALLOCATION STRATEGY TO DRIVE ADDITIONAL VALUE TO SHAREHOLDERS WITH POTENTIAL RETURNS OF CAPITAL VIA MANY MECHANISMS.PURETECH HEALTH: TOTAL REVENUE WAS $17.4 MILLION FOR YEAR ENDED DECEMBER 31, 2021, AN INCREASE OF $5.6 MILLION.

Puretech Health Says Gelesis Receives $30M Plenity Order From Ro

Nov 18 (Reuters) - PureTech Health PLC <PRTC.L>::PURETECH HEALTH PLC - PRTC'S GELESIS RECEIVES $30M PLENITY ORDER FROM RO.

PureTech Says Vor Biopharma Announces Vor33 Granted U.S. FDA Fast Track Designation For Acute Myeloid Leukemia

Sept 10 (Reuters) - PureTech Health PLC <PRTC.L>::PURETECH FOUNDED ENTITY VOR BIOPHARMA ANNOUNCES VOR33 GRANTED U.S. FDA FAST TRACK DESIGNATION FOR ACUTE MYELOID LEUKEMIA.PURETECH HEALTH - VOR REMAINS ON TRACK TO REPORT VOR33'S INITIAL CLINICAL DATA IN FIRST HALF OF 2022.

PureTech Health Says Akili Interactive Introduced New Features To EndeavorRx Treatment

July 22 (Reuters) - PureTech Health PLC <PRTC.L>::PURETECH HEALTH - CO'S FOUNDED ENTITY, AKILI INTERACTIVE INTRODUCED NEW GAMING FEATURES AND FUNCTIONALITIES TO ITS ENDEAVORRX TREATMENT.

PureTech Health Says Gelesis To Become Publicly Traded Co Via Merger With Capstar SPAC

July 19 (Reuters) - PureTech Health PLC <PRTC.L>::PURETECH HEALTH - AT CLOSING, GELESIS IS EXPECTED TO HAVE A PRO FORMA IMPLIED MARKET VALUE OF APPROXIMATELY $1.3 BILLION.PURETECH HEALTH - PURETECH FOUNDED ENTITY GELESIS TO BECOME PUBLICLY TRADED CO VIA MERGER WITH CAPSTAR SPECIAL PURPOSE ACQUISITION CORP.PURETECH HEALTH - TRANSACTION IS EXPECTED TO PROVIDE GELESIS WITH UP TO $376 MILLION OF GROSS PROCEEDS.

Puretech Founded Entity Vor Biopharma Announces Collaboration With Janssen To Develop Engineered Hematopoietic Stem Cell Transplants Combined With A Bi-Specific Antibody Therapy For Acute Myeloi

July 9 (Reuters) - PureTech Health PLC <PRTC.L>::PURETECH FOUNDED ENTITY VOR BIOPHARMA ANNOUNCES COLLABORATION WITH JANSSEN TO DEVELOP ENGINEERED HEMATOPOIETIC STEM CELL TRANSPLANTS COMBINED WITH A BI-SPECIFIC ANTIBODY THERAPY FOR ACUTE MYELOID LEUKEMIA (AML).PURETECH HEALTH - AGREEMENT WAS FACILITATED BY JOHNSON & JOHNSON INNOVATION.PURETECH HEALTH - VOR BIOPHARMA WILL INVESTIGATE COMBINATION OF TWO TECHNOLOGIES INTO A TREATMENT SOLUTION.

PureTech Announces Clinical Trial And Supply Agreement With BeiGene

July 7 (Reuters) - PureTech Health PLC <PRTC.L>::PURETECH ANNOUNCES CLINICAL TRIAL AND SUPPLY AGREEMENT WITH BEIGENE TO EVALUATE LYT-200 AND TISLELIZUMAB IN PATIENTS WITH DIFFICULT-TO-TREAT SOLID TUMORS.PURETECH HEALTH - CLINICAL TRIAL, SUPPLY DEAL WITH AFFILIATE OF BEIGENE FOR POTENTIAL TREATMENT OF DIFFICULT-TO-TREAT SOLID TUMOR INDICATIONS.PURETECH HEALTH - TO INVESTIGATE LYT-200 AS SINGLE AGENT, IN COMBINATION WITH ANTI-CANCER TREATMENTS, INCLUDING CHEMOTHERAPY, OTHER IMMUNOTHERAPIES.PURETECH HEALTH - BEIGENE HAS AGREED TO SUPPLY TISLELIZUMAB FOR USE IN COMBINATION WITH LYT-200.

Puretech Acquires Remaining Interest In Founded Entity Alivio Therapeutics

June 16 (Reuters) - PureTech Health PLC <PRTC.L>::PURETECH ACQUIRES REMAINING INTEREST IN FOUNDED ENTITY ALIVIO THERAPEUTICS.PURETECH HEALTH - ACQUIRED REMAINING 22% SHARES OUTSTANDING IN FOUNDED ENTITY, ALIVIO THERAPEUTICS.

Puretech Health FY Operating Loss Of $119.5 Mln

April 15 (Reuters) - PureTech Health PLC <PRTC.L>::PLC - FINAL RESULTS.FY TOTAL REVENUE OF $11.7 MILLION VERSUS $9.8 MILLION.FY OPERATING LOSS OF $119.5 MILLION VERSUS $135.4 MILLION.HAVE NOT DECLARED DIVIDENDS AND WE DO NOT PLAN TO PAY ANY DIVIDENDS IN FUTURE.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up